XERS
Xeris Biopharma Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.43
−1.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 335.4M | 291.8M | 203.1M | 163.9M | 110.2M |
| Cost of Revenue | 55.9M | 53.4M | 36.8M | 28.6M | 22.6M |
| Gross Profit | 279.5M | 238.4M | 166.2M | 135.3M | 87.6M |
| Operating Expenses | |||||
| R&D Expense | 34.8M | 31.2M | 25.6M | 22.3M | 21.0M |
| SG&A Expense | 208.1M | 182.4M | 163.5M | 146.1M | 137.7M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.0K | — | 10.8M | 10.8M | 10.8M |
| Total Operating Expenses | 242.9M | 213.5M | 199.9M | 179.3M | 169.6M |
| Cost and Expenses | 298.8M | 266.9M | 236.7M | 207.9M | 192.2M |
| Operating Income (EBIT) | 36.6M | 24.9M | (33.6M) | (44.0M) | (81.9M) |
| Non-Operating | |||||
| Interest Income | 5.3M | 4.7M | 5.3M | 4.8M | 2.6M |
| Interest Expense | 28.3M | 29.1M | 33.2M | 26.6M | 14.1M |
| Net Interest Income | (23.0M) | (24.3M) | (27.9M) | (21.9M) | (11.5M) |
| Other Non-Op Income/Expense | (53.8M) | (24.3M) | (23.5M) | (19.5M) | (14.1M) |
| Non-Operating Income (excl Interest) | 32.7M | 24.3M | (7.0M) | (7.1M) | 42.0K |
| EBT (Pre-Tax Income) | (17.2M) | 554.0K | (57.1M) | (63.5M) | (96.1M) |
| Income Tax Expense | — | — | (2.3M) | (1.2M) | (1.4M) |
| Bottom Line | |||||
| Net Income | (17.2M) | 554.0K | (54.8M) | (62.3M) | (94.7M) |
| Earnings from Cont. Ops | (17.2M) | 554.0K | (54.8M) | (62.3M) | (94.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (17.2M) | 554.0K | (54.8M) | (62.3M) | (94.7M) |
| Per Share | |||||
| Basic EPS | ($0.10) | $0.00 | ($0.37) | ($0.45) | ($0.70) |
| Diluted EPS | ($0.10) | $0.00 | ($0.37) | ($0.45) | ($0.70) |
| Revenue Per Share | $1.94 | $1.82 | $1.38 | $1.19 | $0.81 |
| Shares | |||||
| Basic Shares Outstanding | 172.8M | 160.4M | 146.8M | 137.7M | 135.6M |
| Diluted Shares Outstanding | 172.8M | 172.7M | 146.8M | 137.7M | 135.6M |
| Profitability Metrics | |||||
| EBITDA | 16.4M | 12.7M | (14.0M) | (23.7M) | (69.3M) |
| D&A | 12.5M | 12.2M | 12.6M | 13.2M | 12.7M |
| EBIT | 3.9M | 554.0K | (26.6M) | (36.9M) | (82.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026